ArticleCell death discovery2026
Fibroblast adipogenesis restricts hemangioma growth through a PPARγ/Hippo-YAP/TAZ axis that promotes endothelial apoptosis and cell cycle arrest.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangioma (HEM) is the most common benign vascular tumor in infancy and is characterized by a unique progression pattern involving rapid proliferation followed by spontaneous involution. Increasing evidence suggests that the tumor microenvironment plays a critical role in regulating endothelial cell behavior during HEM development. In this study, we investigated how fibroblast (FB) phenotypic remodeling influences hemangioma endothelial cell (HemEC) function. Through single-cell RNA sequencing analysis, we identified extensive communication between FBs and ECs within HEM tissues. Functional experiments revealed that adipogenically differentiated FBs markedly suppressed HemEC proliferation, migration, invasion, and tube formation while promoting apoptosis. Transcriptomic analysis further demonstrated that this inhibitory effect was mediated by activation of the Hippo-YAP/TAZ signaling pathway in ECs. Mechanistically, adipogenic differentiation significantly upregulated PPARG expression in FBs, which in turn triggered Hippo pathway activation in ECs, leading to YAP/TAZ phosphorylation and nuclear exclusion. Importantly, PPARG silencing in FBs or pharmacological inhibition of the Hippo pathway reversed these effects. Collectively, our findings reveal a previously unrecognized microenvironmental regulatory mechanism in which PPARγ-driven fibroblast adipogenesis suppresses HEM progression through activation of the Hippo-YAP/TAZ pathway in endothelial cells. This study provides new insights into stromal-endothelial communication in HEM and suggests that the PPARγ-Hippo signaling axis may represent a potential therapeutic target. Proposed molecular mechanism by which PPARγ-mediated FB adipogenic differentiation regulates Hippo-YAP/TAZ signaling activity in HemECs. Note: Created in Biorender.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.